Concord Biotech Limited Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹1346Market Cap
₹ 14,048 Cr.Stock P/E
58.9ROE
12.5 %RSI
63.13Trend
BullishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
Concord Biotech Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest Concord Biotech Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the Concord Biotech Ltd share price chart currently indicates a Bullish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 1346 |
| RSI (14) | 63.13 |
| 50 DMA | 1238.36 |
| 200 DMA | 1279.49 |
| Trend | Bullish |
| A/D Rating | A+ |
| RS Rating | 55 |
| EPS Rating | 13 |
| TI65 | 1.09 |
| TI65 Trend | Bullish |
Pivot Points Analysis
Daily pivot points for Concord Biotech Limited calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹1404 |
| R2 | ₹1384.8 |
| R1 | ₹1365.4 |
| PP | ₹1346.2 |
| S1 | ₹1326.8 |
| S2 | ₹1307.6 |
| S3 | ₹1288.2 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 14,048 Cr. |
| Current Price | ₹ 1,343 |
| High / Low | ₹ 1,980 / 987 |
| Stock P/E | 58.9 |
| Book Value | ₹ 193 |
| Dividend Yield | 0.56 % |
| ROCE | 17.1 % |
| ROE | 12.5 % |
| Face Value | ₹ 1.00 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 273 | 91 | 47% |
| Jun 2023 | 195 | 54 | 37% |
| Sep 2023 | 262 | 81 | 44% |
| Dec 2023 | 241 | 78 | 44% |
| Mar 2024 | 319 | 95 | 41% |
| Jun 2024 | 216 | 60 | 38% |
| Sep 2024 | 310 | 96 | 43% |
| Dec 2024 | 244 | 76 | 40% |
| Mar 2025 | 430 | 140 | 44% |
| Jun 2025 | 204 | 44 | 30% |
| Sep 2025 | 247 | 63 | 36% |
| Dec 2025 | 278 | 64 | 35% |
| Mar 2026 | 326 | 88 | 36% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 44.08% |
| FIIs | 6.49% |
| DIIs | 8.41% |
| Public | 41.03% |
| No. of Shareholders | 83,296 |
Pros and Cons
Pros
- Strong technical momentum with price holding comfortably above the 50 DMA (1238.36).
Cons
- Valuation metrics appear elevated with a trailing P/E of 58.9, demanding high performance requirements.
Related NSE Stocks
SBI Cards and Payment Services Limited
View Share Price Analysis →Blue Dart Express Limited
View Share Price Analysis →Hindustan Copper Limited
View Share Price Analysis →Suzlon Energy Limited
View Share Price Analysis →Multi Commodity Exchange of India Limited
View Share Price Analysis →Britannia Industries Limited
View Share Price Analysis →Kfin Technologies Limited
View Share Price Analysis →Jain Resource Recycling Limited
View Share Price Analysis →Cummins India Limited
View Share Price Analysis →Bajaj Holdings & Investment Limited
View Share Price Analysis →CESC Limited
View Share Price Analysis →Thermax Limited
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for Concord Biotech Ltd share?
Based on the latest closing data, the technical momentum for Concord Biotech Ltd is currently evaluated as Bullish. The stock is exhibiting an RSI (14) of 63.13, indicating it is trading in a neutral balanced zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (1238.36) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for Concord Biotech Ltd?
According to Classic Pivot Point methodologies, the core trading floor for Concord Biotech Ltd today centers at a Pivot Point (PP) of ₹1346.2. Upside resistance challenges are calculated at R1: ₹1365.4, R2: ₹1384.8, and R3: ₹1404. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹1326.8, S2: ₹1307.6, and S3: ₹1288.2.
How does the fundamental ROE and P/E ratio look for Concord Biotech Ltd?
Concord Biotech Ltd is currently trading with a valuation metrics context of a Stock P/E of 58.9, against a core structural efficiency Return on Equity (ROE) standing at 12.5 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 13, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell Concord Biotech Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Speculative Momentum Phase (Neutral / Hold). Concord Biotech Ltd is trading abov... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of A+, a Relative Strength (RS) ranking of 55, and long-term trend backing from the TI65 indicator (Bullish pattern).